177 related articles for article (PubMed ID: 27416796)
21. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
[TBL] [Abstract][Full Text] [Related]
22. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
[TBL] [Abstract][Full Text] [Related]
23. The equivalent dose contribution from high-dose-rate brachytherapy to positive pelvic lymph nodes in locally advanced cervical cancer.
Lee YC; Rash DL; Stern RL; Mayadev JS
Brachytherapy; 2013; 12(6):555-9. PubMed ID: 23880417
[TBL] [Abstract][Full Text] [Related]
24. External Beam Radiotherapy Interdigitated with High Dose Rate(HDR) Intracavitary Brachytherapy versus External Beam Radiotherapy followed by Sequential HDR Intracavitary Brachytherapy for Locally Advanced Carcinoma Cervix-Randomized Control Study.
Gupta IJ; Ghosh A; Yadav J; Tuteja JS; Gupta R; Srivastava K; Verma M; Gupta S; Srivastava S; Bhatt MLB
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3441-3445. PubMed ID: 37898849
[TBL] [Abstract][Full Text] [Related]
25. Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.
Cheng JC; Peng LC; Chen YH; Huang DY; Wu JK; Jian JJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1010-8. PubMed ID: 14575832
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
27. De-escalation of the cumulative central radiation dose according to the tumor response can reduce rectal toxicity without compromising the treatment outcome in patients with uterine cervical cancer.
Kim KH; Kim S; Kim GE; Koom WS; Kim SW; Nam EJ; Suh CO; Kim YB
Gynecol Oncol; 2015 Dec; 139(3):439-46. PubMed ID: 26456139
[TBL] [Abstract][Full Text] [Related]
28. High dose-rate brachytherapy for elderly patients with uterine cervical cancer.
Chen SW; Liang JA; Yang SN; Lin FJ
Jpn J Clin Oncol; 2003 May; 33(5):221-8. PubMed ID: 12865465
[TBL] [Abstract][Full Text] [Related]
29. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation.
Perez CA; Grigsby PW; Lockett MA; Chao KS; Williamson J
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):855-66. PubMed ID: 10386643
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix.
Nakano T; Kato S; Ohno T; Tsujii H; Sato S; Fukuhisa K; Arai T
Cancer; 2005 Jan; 103(1):92-101. PubMed ID: 15540233
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
32. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
Mayer A; Nemeskéri C; Petneházi C; Borgulya G; Varga S; Naszály A
Strahlenther Onkol; 2004 Apr; 180(4):209-15. PubMed ID: 15057431
[TBL] [Abstract][Full Text] [Related]
33. Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer.
Koh WY; Lim K; Tey J; Lee KM; Lim GH; Choo BA
Gynecol Oncol; 2013 Oct; 131(1):93-8. PubMed ID: 23906655
[TBL] [Abstract][Full Text] [Related]
34. Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer.
Someya M; Hasegawa T; Tsuchiya T; Kitagawa M; Gocho T; Fukushima Y; Hori M; Miura K; Takada Y; Nakata K; Sakata KI
J Radiat Res; 2020 Mar; 61(2):265-274. PubMed ID: 32009177
[TBL] [Abstract][Full Text] [Related]
35. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45-50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable?
Shakespeare TP; Lim KH; Lee KM; Back MF; Mukherjee R; Lu JD;
Int J Gynecol Cancer; 2006; 16(1):277-82. PubMed ID: 16445645
[TBL] [Abstract][Full Text] [Related]
37. Dosimetric parameters that predict late rectal complications after curative radiotherapy in patients with uterine cervical carcinoma.
Hyun Kim T; Choi J; Park SY; Lee SH; Lee KC; Yang DS; Shin KH; Cho KH; Lim HS; Kim JY
Cancer; 2005 Sep; 104(6):1304-11. PubMed ID: 16078262
[TBL] [Abstract][Full Text] [Related]
38. Clinical results of external beam radiotherapy alone with a concomitant boost program or with conventional fractionation for cervical cancer patients who did not receive intracavitary brachytherapy.
Matsuura K; Okabe T; Fujita K; Tanimoto H; Akagi Y; Kagemoto M
J Radiat Res; 2012 Nov; 53(6):900-5. PubMed ID: 22859563
[TBL] [Abstract][Full Text] [Related]
39. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy.
Wang W; Liu X; Meng Q; Zhang F; Hu K
Taiwan J Obstet Gynecol; 2019 May; 58(3):364-369. PubMed ID: 31122526
[TBL] [Abstract][Full Text] [Related]
40. Comparison of chemoradiotherapy with and without brachytherapy as adjuvant therapy after radical surgery in early-stage cervical cancer with poor prognostic factors: An observational study.
Lan ML; Yu X; Xiao H; Zhou P; Hu N; Liu Y; Wang G
Medicine (Baltimore); 2017 Nov; 96(46):e8384. PubMed ID: 29145247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
